Evolus, Inc. (EOLS) |
| 6.27 -0.25 (-3.83%) 07-14 16:00 |
| Open: | 6.57 |
| High: | 6.62 |
| Low: | 6.24 |
| Volume: | 567,719 |
| Market Cap: | 413(M) |
| PE Ratio: | -14.39 |
| Exchange: | NASDAQ Global Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.32 |
| Resistance 1: | 6.91 |
| Pivot price: | 6.84 |
| Support 1: | 6.24 |
| Support 2: | 5.19 |
| 52w High: | 10.2 |
| 52w Low: | 3.86 |
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Financials
| EPS | -0.660 |
| Book Value | -0.440 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.027 |
| Profit Margin (%) | -14.39 |
| Operating Margin (%) | -9.38 |
| Return on Assets (ttm) | -9.1 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 10 Jul 2026
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wed, 08 Jul 2026
Evolus adds Profhilo, a skin-quality injectable sold in 70+ countries - Stock Titan
Fri, 26 Jun 2026
Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Thu, 25 Jun 2026
EOLS Forecast — Price Target — Prediction for 2027 - TradingView
Sun, 21 Jun 2026
Evolus, Inc.(NasdaqGM: EOLS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Thu, 04 Jun 2026
Evolus (EOLS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
